# A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

> **NCT05655221** · PHASE1 · UNKNOWN · sponsor: **Tasly Biopharmaceuticals Co., Ltd.** · enrollment: 56 (estimated)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** B1344
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05655221
- **Lead sponsor:** Tasly Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-30
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-01-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2022-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05655221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05655221, "A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05655221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*